Effects of the DNA topoisomerase II inhibitor, VM26, on transcriptional initiation in vitro.
Inhibitors of DNA topoisomerase II have been shown to influence the expression of specific genes in vivo, leading investigators to suggest that the topological state of certain genes may affect their expression. In the present study, we have examined the effects of the topoisomerase II inhibitor, VM26, on transcriptional initiation in vitro. VM26 inhibited transcriptional initiation from the rat prolactin and adenovirus major late promoters in an in vitro transcription assay using rat pituitary tumor GH3 cell nuclear extracts. Transcriptional initiation from both supercoiled and linear DNA templates was equally inhibited by VM26 in a dose dependent manner. In order to identify sequences around the prolactin promoter recognized by topoisomerase II, we have mapped topoisomerase II cleavage sites using GH3 cell nuclear extracts as a source for the endogenous enzyme. Using a 910 bp genomic DNA fragment containing 423 bp of 5'-flanking sequences from the prolactin gene, we observed five VM26-enhanced topoisomerase II cleavage sites. Some of these sites map to positions near or within previously described regulatory DNA elements, and thus, may provide the structural basis for the sensitivity of prolactin gene expression to topoisomerase II inhibitors in vivo. These data suggest that inhibition of transcriptional initiation was a consequence of VM26 induced cleavage in the promoter region.
Preston
G M
GM
Department of Anatomy, University of Connecticut Health Center, Farmington 06032.
White
B A
BA
D000818:Animals; D002478:Cells, Cultured; D003001:Cloning, Molecular; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011388:Prolactin / Q000235:genetics; D011401:Promoter Regions, Genetic; D051381:Rats; D013713:Teniposide / Q000494:pharmacology*; D059005:Topoisomerase II Inhibitors; D014158:Transcription, Genetic / Q000187:drug effects*
D059005:Topoisomerase II Inhibitors; D011388:Prolactin; D013713:Teniposide; D004250:DNA Topoisomerases, Type II; D011034:Podophyllotoxin